KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Gross Margin: 2013-2025

Historic Gross Margin for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Sep 2025 value amounting to 90.13%.

  • Supernus Pharmaceuticals' Gross Margin rose 14.00% to 90.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.61%, marking a year-over-year decrease of 44.00%. This contributed to the annual value of 88.23% for FY2024, which is 202.00% up from last year.
  • Supernus Pharmaceuticals' Gross Margin amounted to 90.13% in Q3 2025, which was up 0.33% from 89.83% recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Gross Margin registered a high of 90.13% during Q3 2025, and its lowest value of 82.29% during Q2 2021.
  • For the 3-year period, Supernus Pharmaceuticals' Gross Margin averaged around 87.90%, with its median value being 88.65% (2024).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Gross Margin crashed by 1,109bps in 2021 and then surged by 568bps in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Gross Margin (Quarterly) stood at 89.32% in 2021, then crashed by 303bps to 86.28% in 2022, then skyrocketed by 177bps to 88.06% in 2023, then slumped by 304bps to 85.01% in 2024, then increased by 14bps to 90.13% in 2025.
  • Its Gross Margin was 90.13% in Q3 2025, compared to 89.83% in Q2 2025 and 89.48% in Q1 2025.